Related Experiment Video
Updated: Jun 17, 2026
09:05
Measurement of Smooth Muscle Function in the Isolated Tissue Bath-applications to Pharmacology Research
Published on: January 19, 2015
PPARgamma Agonists: Blood Pressure and Edema
1Department of Biology, Indiana University-Purdue University Indianapolis, 723 West Michigan Street, SL 358 Indianapolis, IN 46202, USA.
PPAR Research
|January 14, 2010
Summary
Peroxisome proliferator activated receptor gamma (PPARgamma) agonists used for diabetes can affect blood pressure and cause fluid retention. Understanding these kidney-related mechanisms is key to developing safer treatments.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Peroxisome proliferator activated receptor gamma (PPARgamma) agonists are crucial for managing type 2 diabetes.
- These drugs can cause significant side effects, including fluid retention and hypotension.
- Renal mechanisms are implicated in both the beneficial and adverse effects of PPARgamma agonists.
Purpose of the Study:
- To elucidate the renal mechanisms underlying PPARgamma agonist-induced fluid retention and blood pressure changes.
- To differentiate the pathways responsible for the therapeutic and adverse effects of these drugs.
- To review current hypotheses and recent findings on PPARgamma agonist actions within the kidney.
Main Methods:
- Review and synthesis of existing animal and human study data.
- Analysis of physiological principles related to renal function and PPARgamma signaling.
- Inclusion of recent research exploring novel renal pathways.
Main Results:
- PPARgamma agonists induce changes in kidney function impacting fluid balance and blood pressure.
- Current mechanistic hypotheses present unresolved physiological enigmas.
- Emerging studies suggest alternative renal pathways contributing to observed effects.
Conclusions:
- Understanding renal mechanisms of PPARgamma agonists is vital for therapeutic optimization.
- Distinguishing pathways for blood pressure lowering versus fluid retention is a key challenge.
- Further research into novel renal pathways may offer strategies to mitigate side effects.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...